# Personalis (PSNL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PSNL
## Company Profile
- Ticker: PSNL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 14.21 USD
- Market cap: 1166593031.72 USD
- Last updated: 2026-08-12
## Business Overview
### Precision-Oncology Genomics
Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease.
### NeXT Personal
NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track cancer recurrence from blood. Clinical use includes surveillance in lung and breast cancer. Personalis serves physicians through reimbursed clinical testing and pharmaceutical companies through translational research, clinical-trial and biomarker services.
## Why The Stock Is Moving

As of Aug 12, 2026, PSNL closed up 1.36% at $14.21. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-04 20:01 EST — [Personalis Reports Second Quarter Results and Recent Highlights](https://biopharmsignal.com/news/PSNL/personalis-reports-second-quarter-results-and-recent-highlights-faf41eee) — Source: Personalis
- 2026-07-20 12:30 EST — [Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform](https://biopharmsignal.com/news/PSNL/tempus-to-acquire-personalis-more-tightly-integrating-molecular-residual-disease-403131a5) — Source: Personalis
- 2026-07-14 10:00 EST — [Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain](https://biopharmsignal.com/news/PSNL/personalis-accelerates-global-expansion-with-ukca-marking-for-next-personal-expa-dbe31487) — Source: Personalis
- 2026-06-09 10:00 EST — [Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits](https://biopharmsignal.com/news/PSNL/personalis-enables-global-biopharma-support-with-ce-ivd-marked-specimen-collecti-076f8412) — Source: Personalis
- 2026-06-02 10:00 EST — [Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026](https://biopharmsignal.com/news/PSNL/personalis-highlights-early-colorectal-cancer-recurrence-detection-and-ultrasensitive-mrd-performance-across-a-broad-set-of-tumor-types-at-asco-2026) — Source: Personalis